Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cian HealthcareBOM:542678 49 PB Ratio is 0.19 as of Aug. 12, 2026, which is 74% below its 10-year median of 0.74. GuruFocus rates BOM:542678 with a GF Score™ of 49/100 and a GF Value™ of ₹82.33 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 920 Drug Manufacturers companies, Cian Healthcare ranks better than 98.26% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-12), Cian Healthcare's share price is ₹9.55. Cian Healthcare's Book Value per Share for the quarter that ended in Mar. 2026 was ₹49.77. Hence, Cian Healthcare's PB Ratio of today is 0.19.
The historical rank and industry rank for Cian Healthcare's PB Ratio or its related term are showing as below:
BOM:542678'
s PB Ratio Range Over the Past 10 Years
Min: 0.13 Med: 0.74 Max: 6.65
Current: 0.19
During the past 11 years, Cian Healthcare's highest PB Ratio was 6.65. The lowest was 0.13. And the median was 0.74.
BOM:542678's PB Ratio is ranked better than 98.26% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs BOM:542678: 0.19
During the past 12 months, Cian Healthcare's average Book Value Per Share Growth Rate was -73.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -47.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -28.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 6.50% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Cian Healthcare was 64.60% per year. The lowest was -47.00% per year. And the median was 12.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cian Healthcare PB Ratio Related Terms
Cian Healthcare PB Ratio Historical Data
* Premium members only.
The historical data trend for Cian Healthcare's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:542678 vs ZTS, UTHR, VTRS: PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cian Healthcare's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cian Healthcare PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cian Healthcare's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cian Healthcare's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Cian Healthcare's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cian Healthcare (BOM:542678) has a PB Ratio of 0.19 as of Aug. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cian Healthcare and its competitors. This is 74% below median its historical median of 0.74. Over the past decade, Cian Healthcare's PB Ratio has ranged from 0.13 to 6.65. According to the industry distribution chart, Cian Healthcare ranks #16 out of 920 companies in the Drug Manufacturers industry, placing it in the top 1.7%.
Is Cian Healthcare's PB Ratio too high?
Cian Healthcare's current PB Ratio of 0.19 is 74% below median its 10-year median of 0.74. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 6.65. The Drug Manufacturers industry median PB Ratio is 1.98. Cian Healthcare's value of 0.19 is 90.4% below this industry median. Based on the distribution chart, Cian Healthcare ranks #16 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cian Healthcare has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cian Healthcare's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cian Healthcare ranks #16 out of 920 companies for PB Ratio. This places Cian Healthcare in the top 2% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.98. Cian Healthcare's value of 0.19 is 90.4% below this benchmark. Historically, Cian Healthcare's own PB Ratio has ranged from 0.13 to 6.65 over the past decade. While the company's 10-year median is 0.74 vs. the industry median of 1.98, Cian Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cian Healthcare's current PB Ratio of 0.19 is 90.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cian Healthcare and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cian Healthcare's current PB Ratio is 0.19, which is 74% below median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cian Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Cian Healthcare (BOM:542678) is currently considered Possible Value Trap. The stock's GF Value™ is ₹82.33, compared to a current price of ₹9.55 — trading 88.4% below its estimated fair value. The current PB Ratio is 0.19, which is 74% below median its 10-year median of 0.74 and 90.4% below the Drug Manufacturers industry median of 1.98. Cian Healthcare's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cian Healthcare (BOM:542678), the current PB Ratio is 0.19 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cian Healthcare (BOM:542678) Overvalued in 2026?
Based on GuruFocus' analysis, Cian Healthcare stock appears to be undervalued.
The current stock price of ₹9.55 is trading 88.4% below its estimated GF Value™ of ₹82.33.
GuruFocus considers Cian Healthcare to be Possible Value Trap.
Key valuation signals for BOM:542678:
PB Ratio: 0.19 (74% below median its 10-year median of 0.74)
GF Value™: ₹82.33 vs. price of ₹9.55 (88.4% below fair value)
Industry Position: 90.4% below the Drug Manufacturers median (#16 of 920)
No single metric tells the full story. See the BOM:542678 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cian Healthcare Ltd is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company manufactures multiple product lines, including tablets, capsules, soft gels, liquid orals, ointments/creams and sachets, and cosmetics. Its portfolio comprises gynecology, haematinic, cardio-diabetic, orthopedic, pediatric, dermacosmetic, antibiotic, CNS, vitamins, and nutrient products. The company operates in five sectors: Export, Government Supplies, Merchant Export, Own Brand Franchise Business, and Third Party/Contract Manufacturing.
49GF Score
Get the complete analysis for BOM:542678
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542678 has been successfully added to your 
